Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cc-115. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 20/20 | 0.72 |
| ▸ | PRKDC known ✓ | P78527 | 1/20 | 0.72 |
| ▸ | RPTOR | Q8N122 | 17/20 | 0.72 |
| ▸ | MLST8 | Q9BVC4 | 17/20 | 0.72 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.72 |
| ▸ | CSF1R | P07333 | 1/20 | 0.72 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.72 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cc-115 SCHEMBL29522125 | 1.00 | MTOR (0.72) | MTORRPTORMLST8PIK3CACSF1R | |
| Cc-115 SCHEMBL1767621 | 0.99 | MTOR (0.71) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522183 | 0.89 | MTOR (0.74) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL138204 | 0.89 | MTOR (0.74) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL16186757 | 0.89 | MTOR (0.57) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL138359 | 0.87 | MTOR (0.55) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL136142 | 0.86 | MTOR (0.75) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522078 | 0.86 | MTOR (0.75) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522319 | 0.85 | MTOR (0.76) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL137471 | 0.85 | MTOR (0.76) | MTORRPTORMLST8PIK3CACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131552-B1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARM LLC (US) | 2020-07-15 | — | — | EP | claimed |
| EP-3549940-A1 | PHARMACEUTICAL FORMULATIONS, OF 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL) -3,4-DIHYDROPYRAZINO[2,3-B]PYRAZIN-2(1H)-ONE | Signal Pharmaceuticals, LLC (US) | 2019-10-09 | — | — | EP | claimed |
| US-20180369241-A1 | TREATMENT OF CANCER WITH DNAPK INHIBITORS | CELGENE CORP (US) | 2018-12-27 | — | — | US | claimed |
| US-10052322-B2 | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-08-21 | — | — | US | claimed |
| US-9980963-B2 | Treatment of cancer with dihydropyrazino-pyrazines | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-05-29 | — | — | US | claimed |
| EP-3313403-A1 | TREATMENT OF CANCER WITH DNAPK INHIBITORS | Celgene Corporation (US) | 2018-05-02 | — | — | EP | claimed |
| US-9782427-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-10-10 | — | — | US | claimed |
| US-9771371-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-09-26 | — | — | US | claimed |
| US-9737535-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-08-22 | — | — | US | claimed |
| EP-2740732-B1 | MTOR kinase inhibitors for oncology indications and diseases associated with the MTOR/P13K/AKT pathway | SIGNAL PHARM LLC (US) | 2017-05-17 | — | — | EP | claimed |
| EP-2493472-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2012-09-05 | — | — | EP | claimed |
| US-20120059164-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | PERRIN-NINKOVIC SOPHIE (US) | 2012-03-08 | — | — | US | claimed |
| US-8110578-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-02-07 | — | — | US | claimed |
| WO-2012016113-A1 | BIOMARKER ASSAYS FOR DETECTING OR MEASURING INHIBITION OF TOR KINASE ACTIVITY | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | WO | claimed |
| US-20120028972-A1 | BIOMARKER ASSAYS FOR DETECTING OR MEASURING INHIBITION OF TOR KINASE ACTIVITY | SIGNAL PHARMACEUTICALS, LLC | 2012-02-02 | — | — | US | claimed |
| EP-2358718-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | Signal Pharmaceuticals, LLC (US) | 2011-08-24 | — | — | EP | claimed |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | claimed |
| WO-2011053518-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-05-05 | — | — | WO | claimed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | claimed |
| WO-2010062571-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-06-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369241-A1 | TREATMENT OF CANCER WITH DNAPK INHIBITORS | DKK1, WNT1, DCK | MTOR 403/4885PRKDC 417/4885RPTOR 2148/4885 |
| US-20120028972-A1 | BIOMARKER ASSAYS FOR DETECTING OR MEASURING INHIBITION OF TOR KINASE ACTIVITY | MTOR, RPTOR, ULK1 | MTOR 1/4885PRKDC 38/4885RPTOR 2/4885 |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885PRKDC 1932/4885RPTOR 3/4885 |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | MTOR 595/4885PRKDC 4783/4885RPTOR 478/4885 |
| US-10052322-B2 | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one | CYP3A7, UGT1A7, UGT2B7 | MTOR 3661/4885PRKDC 1189/4885RPTOR 4541/4885 |
| US-20120059164-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885PRKDC 2125/4885RPTOR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.